Elevation of glutathione as a therapeutic strategy in Alzheimer disease

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

卷:1822

Review

Pocernich, Chava B.^1,2  Butterfield, D. Allan^1,2,3 

[1] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA

[2] Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40506 USA

[3] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA

关键词: Alzheimer disease (AD);    Mild cognitive impairment (MCI);    Amyloid beta-peptide;    Glutathione (GSH);    N-acetylcysteine (NAC);    gamma-Glutamylcysteine ethyl ester;   

DOI  :  10.1016/j.bbadis.2011.10.003

来源: Elsevier

【 摘 要 】

Oxidative stress has been associated with the onset and progression of mild cognitive impairment (MCI) and Alzheimer disease (AD). AD and MCI brain and plasma display extensive oxidative stress as indexed by protein oxidation, lipid peroxidation, free radical formation, DNA oxidation, and decreased antioxidants. The most abundant endogenous antioxidant, glutathione, plays a significant role in combating oxidative stress. The ratio of oxidized to reduced glutathione is utilized as a measure of intensity of oxidative stress. Antioxidants have long been considered as an approach to slow down AD progression. In this review, we focus on the elevation on glutathione through N-acetyl-cysteine (NAC) and gamma-glutamylcysteine ethyl ester (GCEE) as a potential therapeutic approach for Alzheimer disease. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease. (C) 2011 Elsevier B.V. All rights reserved.

【 授权许可】

Free